Enclomiphene Citrate in Adults 65 and Older: What the Evidence Says About Safety

Why Geriatric Safety Deserves Its Own Discussion

Men over 65 account for a growing share of testosterone-deficiency diagnoses, yet most enclomiphene data come from younger cohorts. The pharmacokinetic and pharmacodynamic profile of a SERM in a 70-year-old differs from that in a 40-year-old because of lower glomerular filtration rates, reduced hepatic metabolism, shifts in body composition, and a higher baseline burden of comorbid disease. A 2016 study by Kim et al. in BJU International confirmed that clomiphene citrate (the racemic mixture containing enclomiphene) restored serum testosterone to eugonadal levels while preserving spermatogenesis in men with secondary hypogonadism [1]. That trial, however, enrolled predominantly younger men. Extrapolating those results to a geriatric population requires accounting for age-specific pharmacology and competing risks that younger patients rarely face.

The Endocrine Society's 2018 clinical practice guideline recommends against routine testosterone therapy in men over 65 unless symptoms are clear and benefits outweigh risks [2]. While enclomiphene is not exogenous testosterone, it raises endogenous levels through the same hypothalamic-pituitary-gonadal axis. The downstream cardiovascular and thromboembolic considerations therefore overlap.

How Enclomiphene Works Differently From Exogenous Testosterone

Enclomiphene is the trans-isomer of clomiphene citrate. It selectively antagonizes estrogen receptors in the hypothalamus, removing negative feedback and prompting a rise in gonadotropin-releasing hormone (GnRH). This cascade increases luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which together stimulate Leydig cells to produce more testosterone. The distinction from exogenous testosterone matters: endogenous production preserves intratesticular testosterone concentrations, maintaining spermatogenesis and avoiding the testicular atrophy associated with injected or topical testosterone [1].

For older men who retain some testicular reserve, this mechanism is relevant. Fertility preservation is less often a clinical priority after 65, but the physiologic difference between endogenous and exogenous pathways also affects estradiol levels, hematocrit response, and hypothalamic-pituitary-adrenal crosstalk. A 2020 meta-analysis in the Journal of Clinical Endocrinology & Metabolism found that SERMs increased testosterone by a mean of 261 ng/dL without significantly raising hematocrit, a meaningful distinction in older men already at elevated polycythemia risk [3].

Cardiovascular Risk: The Central Concern

Cardiovascular safety is the single most scrutinized aspect of testosterone modulation in older men. The TTrials cardiovascular substudy (N=790, mean age 72) found that one year of testosterone gel increased coronary artery plaque volume by a statistically significant margin compared with placebo [4]. That finding prompted the FDA to add a cardiovascular warning to all testosterone products in 2015.

Enclomiphene raises testosterone through a different route, but the hormone itself still acts on vascular endothelium, erythropoiesis, and platelet aggregation. No completed trial has measured major adverse cardiovascular events (MACE) with enclomiphene specifically in men 65 and older. Until such data exist, clinicians should apply the same risk-stratification frameworks used for exogenous testosterone.

The TRAVERSE trial (N=5,246, ages 45 to 80) published in the New England Journal of Medicine in 2023 found that transdermal testosterone did not increase the incidence of MACE compared with placebo over a mean follow-up of 33 months [5]. That result modestly reassured the field, but TRAVERSE excluded men with recent MI, stroke, or NYHA class III/IV heart failure. Older adults with those conditions remain a population where any testosterone-raising therapy warrants close monitoring.

Practical screening before prescribing enclomiphene to a patient over 65 should include a resting ECG, lipid panel, fasting glucose or HbA1c, and a clinical assessment of heart failure symptoms. Patients with a history of venous thromboembolism (VTE) deserve particular caution: SERMs as a class carry a VTE signal, primarily studied in female breast cancer populations but biologically plausible in men.

Renal Function and Drug Clearance

Age-related decline in renal function is near-universal. The average 75-year-old has a GFR roughly 30% lower than a healthy 30-year-old. Enclomiphene is hepatically metabolized, but renal clearance of metabolites still matters. No published pharmacokinetic study has characterized enclomiphene disposition in adults with an estimated GFR below 60 mL/min/1.73 m².

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines classify CKD stage 3a (GFR 45 to 59) as mild-to-moderate impairment and stage 3b (GFR 30 to 44) as moderate-to-severe [6]. In the absence of drug-specific data, a reasonable clinical approach is to start at the lower dose (12.5 mg daily), monitor renal function at 4 to 6 weeks, and hold or discontinue if GFR drops or if drug-related side effects (visual disturbances, headache, GI symptoms) emerge at levels disproportionate to the dose.

Testosterone itself affects renal hemodynamics. A 2019 study in the American Journal of Kidney Diseases found that testosterone therapy was associated with a small but measurable increase in serum creatinine, likely reflecting increased muscle mass rather than true nephrotoxicity [7]. Clinicians should interpret creatinine-based GFR estimates cautiously in men whose lean mass changes on therapy.

Polypharmacy and Drug-Drug Interactions

Adults over 65 take a median of five prescription medications. Enclomiphene is metabolized primarily by CYP2D6 and CYP3A4. Commonly prescribed drugs that inhibit these enzymes, including fluoxetine, paroxetine, amiodarone, and certain azole antifungals, could raise enclomiphene plasma concentrations. Conversely, CYP3A4 inducers such as carbamazepine, phenytoin, and rifampin may reduce its efficacy.

The interaction burden is not theoretical. A pharmacoepidemiologic study published in JAMA Internal Medicine found that 15% of older adults are exposed to at least one clinically significant drug-drug interaction at any given time [8]. Before prescribing enclomiphene, a pharmacist-led medication reconciliation is a sensible step.

Anticoagulants warrant special attention. Warfarin, a CYP2C9 substrate, has a narrow therapeutic index. While enclomiphene's effect on CYP2C9 is not well characterized, the structurally related zuclomiphene (the cis-isomer in racemic clomiphene) has shown weak inhibition of CYP2C9 in vitro. Patients on warfarin should have INR checked within two weeks of starting enclomiphene.

Direct oral anticoagulants (DOACs) like apixaban and rivarelbaan are CYP3A4 substrates. Co-administration with a drug that competes for the same enzyme could alter DOAC levels, raising bleeding risk. This interaction has not been studied clinically, but pharmacologic plausibility justifies monitoring.

Vision Changes and Ocular Safety

Clomiphene citrate carries a well-documented risk of visual disturbances, including blurred vision, scotomata, and photopsias. These effects are attributed primarily to zuclomiphene, the cis-isomer, which accumulates due to a longer half-life. Enclomiphene, as the isolated trans-isomer, has a shorter half-life and lower reported incidence of visual side effects in early clinical trials. A phase II trial of enclomiphene reported visual symptoms in fewer than 2% of participants, compared with 5 to 10% historically reported with racemic clomiphene [9].

Older adults, however, have a higher baseline prevalence of cataracts, macular degeneration, and diabetic retinopathy. Even a low absolute risk of drug-induced visual change can be clinically meaningful when layered onto pre-existing ocular disease. A baseline ophthalmologic exam is not mandatory per any guideline, but it is prudent in patients with known eye disease. Any new visual symptom should prompt immediate discontinuation.

Falls, Fractures, and Musculoskeletal Considerations

Falls are the leading cause of injury-related death in adults 75 and older, per the CDC's National Center for Injury Prevention [10]. Testosterone deficiency contributes to sarcopenia and reduced balance. Raising testosterone may improve muscle mass and reduce fall risk over time. The TTrials Physical Function substudy showed a modest improvement in 6-minute walk distance among men over 65 treated with testosterone gel for one year [11].

Whether enclomiphene confers the same musculoskeletal benefit depends on the testosterone levels achieved and sustained. If enclomiphene raises total testosterone into the 400 to 600 ng/dL range, the downstream effects on muscle protein synthesis should theoretically parallel those of exogenous testosterone at similar serum concentrations. No trial has directly measured fall rates or grip strength in older men taking enclomiphene.

A separate concern is bone density. SERMs have mixed skeletal effects in men. In postmenopausal women, raloxifene (another SERM) reduces vertebral fracture risk, but male bone biology differs. The Osteoporotic Fractures in Men (MrOS) study found that low testosterone and low estradiol independently predicted fracture risk in older men [12]. By raising both testosterone and, through aromatization, estradiol, enclomiphene could be theoretically protective. DEXA scans at baseline and 12 to 24 months provide objective data.

Monitoring Protocol for Older Adults

A structured monitoring plan reduces the risk of adverse events and ensures the drug remains beneficial.

Baseline (before first dose):

• Total and free testosterone, LH, FSH, estradiol
• Complete metabolic panel including creatinine and eGFR
• Complete blood count with hematocrit
• Lipid panel, fasting glucose or HbA1c
• PSA (prostate-specific antigen)
• Resting 12-lead ECG
• Medication reconciliation for CYP2D6/3A4 interactions
• Vision symptom inventory

Week 4 to 6:

• Repeat total testosterone, LH, hematocrit
• Reassess symptoms (energy, libido, mood)
• Check INR if on warfarin
• Screen for visual disturbances

Every 3 to 6 months thereafter:

• Total testosterone, hematocrit, PSA
• Renal function (eGFR)
• Clinical reassessment: is the drug still providing benefit that justifies continued use?

Annual:

• Lipid panel
• DEXA if osteopenia or osteoporosis was present at baseline
• Ophthalmologic evaluation if visual symptoms arise

Hematocrit above 54% should prompt dose reduction or discontinuation regardless of testosterone level, consistent with the AUA/Endocrine Society consensus on testosterone therapy monitoring [2].

Deprescribing: When to Stop

Not every 65-year-old who starts enclomiphene should remain on it indefinitely. The concept of deprescribing, systematically reducing or discontinuing medications whose risks now outweigh benefits, applies directly.

Reasons to stop enclomiphene in older adults include: hematocrit persistently above 54%, new VTE or cardiovascular event, visual disturbances, PSA rise exceeding 1.4 ng/mL per year (a threshold flagged by the AUA Early Detection of Prostate Cancer guideline) [13], worsening renal function attributed to the drug, or resolution of hypogonadal symptoms through other means (weight loss, improved sleep, discontinuation of an offending medication).

A trial off-period of 8 to 12 weeks can help determine whether the patient's symptoms return. If testosterone falls but the patient feels no worse, the drug was treating a lab value, not a disease. Treat the patient, not the number.

Compounding Pharmacy Considerations

Enclomiphene is not available as an FDA-approved commercial product. All current supply comes through compounding pharmacies. This introduces variability in potency, purity, and bioavailability that does not exist with manufactured pharmaceuticals. The FDA's guidance on compounded drugs emphasizes that compounded products are not evaluated for safety, efficacy, or manufacturing quality under the same standards as approved drugs [14].

For geriatric patients, this variability carries higher stakes. A 10% potency overshoot in a 25 mg capsule delivers 27.5 mg, a difference that younger patients may tolerate easily but that could push an older patient's hematocrit or estradiol into concerning territory. Clinicians should use pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or verified through state board inspection records.

How Enclomiphene Compares to Other Options in Older Men

Exogenous testosterone (injections, gels, pellets) remains the most studied treatment for male hypogonadism. For men over 65, the TRAVERSE trial provides the best available safety data for exogenous testosterone [5]. Enclomiphene's advantage is preserving the HPG axis and avoiding testicular suppression. Its disadvantage is the lack of equivalent long-term safety data.

Other SERMs, specifically tamoxifen and raloxifene, have been used off-label in men, but neither has the hypothalamic selectivity of enclomiphene. Tamoxifen carries a higher VTE risk and is associated with hepatic steatosis. Human chorionic gonadotropin (hCG) stimulates Leydig cells directly but requires subcutaneous injection and does not address pituitary-level pathology.

For a geriatric patient with mild symptoms and borderline-low testosterone (250 to 350 ng/dL), lifestyle optimization (resistance training, sleep improvement, weight management) may eliminate the need for any pharmacotherapy. The ENRGY trial demonstrated that structured exercise improved testosterone levels and functional capacity in sedentary older men without medications [15].